MedTrace Logo

XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach

NCT01798251 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-05-06

No results posted yet for this study

Summary

To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of elderly advanced gastric cancer (AGC) by comparing it with that of XELOX regimen.

Conditions

Interventions

DRUG

Oxaliplatin

Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks

DRUG

Capecitabine

capecitabine 850mg/m2 bid, d1-14, every 3 weeks

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Yuxian BAI, PhD · The tumor hospital of Harbin medical university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798251 on ClinicalTrials.gov